Monotherapy for the treatment of multiple myeloma in adults, who have received at least 4 prior therapies & whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, & an anti-CD38 monoclonal Ab, & who have demonstrated disease progression on the last therapy.
Reports of corneal adverse reactions. Perform ophth examination (including visual acuity & slit lamp examination) at baseline, before the subsequent 3 treatment cycles, & as clinically indicated during treatment. Administer preservative-free artificial tears at least 4 times daily beginning on the 1st day of infusion & continuing until completion of treatment to reduce corneal symptoms. Avoid using contact lenses until the end of treatment. Reports of thrombocytopenic events. Obtain complete blood counts at baseline & monitor during treatment, as clinically indicated. Reports of infusion-related reactions. Moderate influence on the ability to drive or use machines. Patients w/ severe renal impairment. Patients w/ moderate or severe hepatic impairment. May impair fertility in females & males of reproductive potential. Women of child-bearing potential should use effective contraception during treatment & for 4 mth after the last dose. Men w/ female partners of child-bearing potential should use effective contraception during treatment & for 6 mth after the last dose. Pregnancy. Discontinue breast-feeding prior to initiating treatment & for 3 mth after the last dose. Childn & adolescents <18 yr. Patients w/ body wt <40 or >130 kg.
Sign Out
